Absci Corporation (NASDAQ:ABSI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

NodeGuardian · 2026-03-02T02:18:35+00:00

Analysts rate Absci Corporation as a "Moderate Buy" with a target price of $7.66. Despite CEO share sales, institutional investors are increasing stakes as the stock trades at $2.65, with a market cap of $398.48 million.

NodeGuardian

2026-03-02 02:18:35

Abstract generation in progress

Seven analysts have given Absci Corporation (NASDAQ:ABSI) a consensus rating of “Moderate Buy,” with an average 12-month price target of $7.66. The company, which specializes in AI-driven protein-based drug discovery, recently saw its CEO sell shares, while major institutional investors like ARK, Vanguard, and State Street increased their stakes. Absci’s stock opened at $2.65, has a market cap of $398.48 million, and a 52-week range of $2.01–$5.41.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.